Capstan Therapeutics to Participate in Upcoming Scientific Conferences and Present New Preclinical Data in Support of Lead Anti-CD19 In Vivo CAR-T Candidate, CPTX2309
SAN DIEGO--(BUSINESS WIRE)--Capstan Therapeutics, Inc. ('Capstan'), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that the Company will present at upcoming scientific conferences and showcase new preclinical data on CPTX2309, Capstan's lead anti-CD19 in vivo CAR-T candidate, at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, LA.
'Among the diverse set of presentations showcasing Capstan's non-viral CellSeeker™ platform, we are particularly encouraged by new preclinical data in support of our in vivo anti-CD19 CAR-T program, which demonstrate that a compact two-dose cycle was sufficient to induce rapid and deep B cell depletion in blood and tissues of non-human primates,' said Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D at Capstan. 'These preclinical data highlight the potency of B cell depletion achievable with a transient in vivo CAR mRNA approach, without the need for lymphodepletion, and set the stage for clinical evaluation of CPTX2309.'
Featured Presentation:
American Society of Gene & Cell Therapy (ASGCT) 28 th Annual Meeting
Date:
Location: New Orleans, LA
Oral presentation title: A Two-Infusion Regimen with a Novel In Vivo Non-Viral Chimeric Antigen Receptor (CAR) Achieves up to 90% CD8+ T Cell Engineering and Tissue Depletion of Target Cells in Non-Human Primates (NHPs)
Presenter: Haig Aghajanian, Ph.D., Vice President of Research, Co-founder
Session title: CAR T Innovations in Autoimmune and Infectious Disease and Allergy
Date and time: May 15, 2025, 5:00 p.m. - 5:15 p.m. CT
Location: Room 393-396
Additional Presentations feature progress with our CellSeeker TM platform technology applicable to both mRNA and gene editing payloads:
Cellicon Valley '25: The Future of Cell and Gene Therapies
Date: Apr 30-May 2, 2025
Location: Philadelphia, PA
Oral Presentation Title: Leading the Charge for In Vivo Cell Therapy for The Treatment of Autoimmune Disorders
Presenter: Laura Shawver, Ph.D., Chief Executive Officer
Session title: Plenary Session 2, Leadership in Cell and Gene Therapies: The XX Factor
Date and Time: May 1, 2025, 10:20 a.m. - 10:30 a.m. ET
International Society of Cell & Gene Therapy (ISCT) 2025
Date: May 7-10, 2025
Location: New Orleans, LA
Poster title: Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved Diseases
Presenter: Haig Aghajanian, Ph.D., Vice President of Research, Co-founder
Poster number: 901
Session title: Poster Networking Reception 1; Immunotherapy (CAR-T, T Reg, NK Cells, etc.)
Date and time: May 7, 2025, 7:00 p.m. - 8.30 p.m. CT
21 st Annual PEGS Boston: The Essential Protein & Antibody Engineering Summit
Date: May 12-16, 2025
Location: Omni Boston Hotel at the Seaport, Boston, MA
Title: Chairperson's Remarks
Presenter: Adrian Bot, M.D., Ph.D., Chief Scientific Officer
Track: In Vivo CAR T Engineering: Moving into the Clinic
Date and time: May 15, 2025, 8:25 a.m. ET
Oral presentation title: In vivo mRNA-Based CAR T Cell Engineering for Treatment of B Cell Disorders
Presenter: John Rossi, Vice President, Translational Medicine
Track: In Vivo CAR T Engineering: Moving into the Clinic
Date and time: May 15, 2025, 9:00 a.m. ET
American Society of Gene & Cell Therapy (ASGCT) 28 th Annual Meeting
Date: May 13-17, 2025
Location: New Orleans, LA
Science Symposium: Targeted Nanosystems For Gene Transfer And Editing: Beyond Delivery To The Liver
Oral presentation title: In vivo immune cell engineering using targeted nanoparticles
Presenter: Priya Karmali, Ph.D., Chief Technology Officer
Date and time: May 16, 2025, 4:10 p.m. - 4:35 p.m. CT
Location: NOLA Theater B
Poster: Efficient In Vivo Gene Editing of T Cells Utilizing Novel Targeted Lipid Nanoparticles
Presenter: Esther Chen, Ph.D., Principal Scientist, R&D
Session title: Tuesday Poster Reception
Date and time: May 13, 2025, 6:00 p.m. - 7:30 p.m. CT
Location: Poster Hall I2
Poster: Effective Gene Editing in Hematopoietic Stem and Progenitor Cells (HSPCs) through a Novel Targeted Lipid Nanoparticle
Presenter: Esther Chen, Ph.D., Principal Scientist, R&D
Session title: Thursday Poster Reception
Date and time: May 15, 2025, 5:30 p.m. - 7:00 p.m. CT
Location: Poster Hall I2
TIDES USA
Date: May 19-22, 2025
Location: Manchester Grand Hyatt San Diego, San Diego, CA
Oral presentation title: In Vivo Engineering of Cells Using Targeted Lipid Nanoparticles
Presenter: Priya Karmali, Ph.D., Chief Technology Officer
Track: mRNA Technology and Applications
Date and time: May 21, 2025, 2:00 p.m. PT
About Capstan Therapeutics, Inc. (www.capstantx.com)
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan's CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Propedix Inc. Announces Appointment of William Haegele to Board of Directors
BOSTON, June 4, 2025 /PRNewswire/ -- Propedix, a leading organization in Anti-infective topical Dermatology treatments, is pleased to announce a significant addition to its Board of Directors. Bill Haegele has been appointed to the Board of Directors as its first Independent Director and will play a pivotal role in driving the company's strategic initiatives and fostering continued growth. Propedix's first product, Dryello™ is a soon to be launched over-the-counter treatment for Athlete's Foot (tinea pedis), intended to both treat and prevent the fungal infection and its symptoms. With a proven track record of success in life sciences, public accounting, board governance, and general management, Mr. Haegele brings a wealth of experience and expertise to Propedix. A retired KPMG Partner, he offers deep knowledge in corporate governance and risk management. Bill has held leadership and board roles at several life sciences companies and is widely recognized for his innovative thinking, strategic leadership, and comprehensive understanding of the industry landscape. "We are thrilled to welcome Bill to the Board of Directors," said Niv Caviar, CEO of Propedix. "His visionary approach, strategic mindset, and passion for life science innovation align perfectly with our company's values and objectives. We are confident that his leadership will help propel us to new heights and reinforce our position as an industry leader." In this role, Bill will provide governance oversight over the company's financial, accounting, and corporate functions. His strategic vision and ability to help grow the company will be instrumental in guiding Propedix towards continued success and expansion as the Company develops and launches innovative dermatological topical anti-infective technologies. Mr. Haegele expressed enthusiasm about joining Propedix: "I am honored to join the Propedix team and look forward to contributing to the company's growth and success. I am confident that the Company's management team's decades of experience in developing and commercializing dermatological and anti-infective technologies will establish Propedix as a leader in innovative biopharma delivery and formulation solutions." About Propedix Propedix is a leading biopharma and consumer health company dedicated to advancing innovative treatments in topical dermatology and anti-infectives. Through a commitment to innovation, Propedix strives to provide effective, clinically tested solutions to fungal conditions. The Propedix team works diligently to expand the world of antifungal and anti-pathogen treatment through the use of their propriety delivery and formulation technology. Propedix has established itself as a trusted name in the industry, centering around improving the quality of life for each patient. About Dryello™ Dryello™ is a novel treatment for Athlete's foot that has been clinically tested to demonstrate strong effectiveness in mycological (fungal) cure and the reduction of symptoms associated with such infections including itch, perspiration, maceration, and scaling. Dryello's unique technology formulation and the supporting clinical data will be made available to the public upon commercial launch by early summer. View original content to download multimedia: SOURCE Propedix Inc.
Yahoo
an hour ago
- Yahoo
As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options
Spherix Global Insights' new patient audit on transfusion-dependent thalassemia reveals strong physician interest in emerging treatments like mitapivat and etavopivat, and provides insight into ideal candidates for curative gene therapies. EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent thalassemia patients remain tethered to long-term transfusion support. Transfusions, while providing symptom relief, in turn create logistical barriers and their own clinical challenges. New data from Spherix Global Insights' independent chart audit, Patient Chart Dynamix™: Transfusion Dependent Thalassemia 2025 (US), is based on insight from 81 real-world patient charts submitted by 49 US-based hematologists. These data paint a complex picture of therapeutic inertia, growing anticipation for emerging treatments, and deep-seated frustration with limitations of current treatment options. Most transfusion-dependent beta thalassemia patients follow some regular transfusion schedule. That said, many receive them at relatively extended intervals: often once a month or even less frequently, though a small subset still require more frequent transfusions. This variation in treatment patterns, along with persistent symptoms and unmet needs highlighted in the chart audit, points to a strong opportunity for new therapies to improve care for a broad range of patients. Among surveyed hematologists, mitapivat (Agios) currently holds a slight edge in name recognition over etavopivat (Novo Nordisk). Interestingly, despite this difference in familiarity, physicians identified slightly more patients as potential candidates for etavopivat, hinting at a broader perceived clinical fit once awareness and understanding of the agent catch up. Chart audit data allows users to probe further into specific patient types which physicians perceive as better fits for either agent, as well as those who they do not perceive as candidates. This growing interest in emerging oral therapies reflects a broader desire among hematologists for more accessible, lower-burden treatment options. While most patients are theoretically eligible for curative approaches like gene therapy, the market still favors lower-barrier alternatives. These alternatives include oral therapies that do not require referral to specialized centers or extensive pre-conditioning, and brands with which they are more familiar given other indications such as Reblozyl (Bristol Myers Squibb). Disease-modifying therapies that are easier to prescribe and integrate into routine practice have the promise to significantly improve the lives of patients who would not qualify or want gene therapy. Access barriers compound the issue, with over half of physicians voicing frustration over payer restrictions that make it difficult to initiate optimal care. These challenges highlight a critical need – not just for clinical innovation, but also for strong manufacturer support in navigating reimbursement and expanding access. As the beta thalassemia landscape continues to evolve, hematologists are increasingly looking toward emerging therapies that are easier to prescribe, carry fewer logistical burdens than gene therapy, and offer clear reductions in transfusion dependency. Products like mitapivat and etavopivat are well-positioned to address this gap, assuming familiarity, confidence, and access grow in tandem – but the goal to cure patients of hemoglobinopathies still carries heavy weight, with desire to treat with gene therapy consistently growing. Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the 'why' behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284 in to access your portfolio
Yahoo
an hour ago
- Yahoo
Heat records in jeopardy as season's first 90-degree readings expected in Northwest
Mother Nature is about to turn up the thermostat in the Pacific Northwest, with record high temperatures in the forecast for a few days beginning this weekend, say AccuWeather meteorologists. For some areas away from the coast and in valleys, it will be the first time venturing into the 90s this year, while many other communities will make it into the 80s, well above historical averages for early June. "Those with outdoor plans this weekend will want to schedule their activities in the morning or evenings to avoid the peak heating hours during the day," AccuWeather Senior Meteorologist Dan Pydynowski said. "If you must be outside, drink plenty of water and take as many breaks in the shade and indoors in air conditioning as possible." The increase in temperature will be driven by a building area of high pressure across the West, replacing an area of low pressure which was leading to locally heavy showers and thunderstorms into midweek, especially across the Southwest and Rockies. After another rather typical early-June day temperature-wise on Wednesday, the warmth will begin to ratchet up on Thursday and Friday before records begin to be challenged on Saturday. "The first 90-degree readings of the year thus far are expected in Portland, Oregon, this weekend," said Pydynowski. "Both Saturday and Sunday's forecast high temperatures will challenge or even break daily records." The record high temperature in Portland on Saturday of 93 from 1948 may be safe, but it appears the daily record of 94 from 1955 on Sunday is in jeopardy of tumbling, with AccuWeather forecasters expecting a high temperature well into the the app? Unlock AccuWeather Alerts™ with Premium+ Typically, Portland experiences its first 90-degree reading of the year in mid- to late June, so the intrusion of warmth expected this weekend is a couple of weeks ahead of the historical average. "The historical average first date for 95-degree heat in Portland is July 21," pointed out AccuWeather Senior Meteorologist Chad Merrill. Seattle, while not expected to venture into the 90s, will not be exempt from the warmth. High temperatures well into the 80s are on tap for Sunday and Monday, with Sunday's forecast high close to the daily record of 87 set a decade ago. Smaller towns east of the Cascades will also be roasting beginning this weekend. "Spokane, Washington, will flirt with daily records Saturday, Sunday and Monday with highs in the lower 90s expected," added Pydynowski. "Meanwhile, Omak, Washington, will challenge a long-standing record by next Monday, as the high tops out near 99, which is a mark that has stood for over 100 years, since 1918." While heat waves of this magnitude are not unusual in the Pacific Northwest, especially during midsummer, they can be impactful and potentially deadly. Only 53 percent of buildings in Washington state have air conditioning equipment, the second-lowest percentage in the U.S. behind Alaska, according to data from the Haas School of Business at the University of California in Berkeley. In Oregon, only about three-quarters of buildings have such cooling capabilities. "In the wake of a deadly heat wave in June 2021, a study by the National Weather Service indicated homes without air conditioning were warmest between 9 p.m. and 11 p.m.," said Merrill. "For those without air conditioning, staying at a friend's or relative's home with air conditioning overnights this weekend is advised." For those looking for a reprieve from the early-season heat, it is forecast to fade by the middle of next week, as the area of high pressure moves east. Temperatures will return to more typical readings in the 60s and 70s. Want next-level safety, ad-free? Unlock advanced, hyperlocal severe weather alerts when you subscribe to Premium+ on the AccuWeather app. AccuWeather Alerts™ are prompted by our expert meteorologists who monitor and analyze dangerous weather risks 24/7 to keep you and your family safer.
